Small artery remodeling in obesity and insulin resistance

Current Vascular Pharmacology

Volumn 12, Issue 3, 2014, Pages 427-437

  Briones, Ana M ^a   Aras López, Rosa ^a   Alonso, María J ^a   Salaices, Mercedes ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Insulin resistance; Obesity; Remodeling; Small arteries; Stiffness

Indexed keywords

ADIPONECTIN; ALAGEBRIUM; CANDESARTAN; COMPLEMENT COMPONENT C3; CYCLOOXYGENASE 2; ELASTIN; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; MATRIX METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTERY REMODELING; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EXERCISE; EXTRACELLULAR MATRIX; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHY; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; OXIDATIVE STRESS; PHYSICAL ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINOPATHY; TISSUE PERFUSION; VASCULAR REMODELING;

EID: 84922393833     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666140423221319     Document Type: Article

References (144)

1. [1] Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular dis- ease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115(12): 1544-50.
2. [2] Davel AP, Wenceslau CF, Akamine EH, et al. Endothelial dysfunc- tion in cardiovascular and endocrine-metabolic diseases: an update. Braz J Med Biol Res 2011; 44(9): 920-32.
3. [3] Samaranayake NR, Ong KL, Leung RY, Cheung BM. Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008. Ann Epidemiol 2012; 22(5): 349-53.
4. [4] Maachi M, Pieroni L, Bruckert E, et al. Systemic low-grade in- flammation is related to both circulating and adipose tissue TNFal- pha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 2004; 28(8): 993-7.
5. [5] Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6(10): 772-83.
6. [6] Sturm W, Sandhofer A, Engl J, et al. Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. Obesity (Silver Spring) 2009; 17(9): 1783-8.
7. [7] Aghamohammadzadeh R, Heagerty AM. Obesity-related hyperten- sion: epidemiology, pathophysiology, treatments, and the contribu- tion of perivascular adipose tissue. Ann Med 2012; 44 (Suppl 1): S74-84.
8. [8] Rizzoni D, De Ciuceis C, Porteri E, Semeraro F, Rosei EA. Struc- tural alterations in small resistance arteries in obesity. Basic Clin Pharmacol Toxicol 2012; 110(1): 56-62.
9. [9] Prasad A, Quyyumi AA. Renin-angiotensin system and angio- tensin receptor blockers in the metabolic syndrome. Circulation 2004; 110(11): 1507-12.
10. [10] Gálvez-Prieto B, Bolbrinker J, Stucchi P, et al. Comparative ex- pression analysis of the renin-angiotensin system components be- tween white and brown perivascular adipose tissue. J Endocrinol 2008; 197(1): 55-64.
11. [11] Lu C, Su LY, Lee RM, Gao YJ. Mechanisms for perivascular adi- pose tissue-mediated potentiation of vascular contraction to peri- vascular neuronal stimulation: the role of adipocyte-derived angio- tensin II. Eur J Pharmacol 2010; 634(1-3): 107-12.
12. [12] Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin- angiotensin system: a target of and contributor to dyslipidemias, al- tered glucose homeostasis, and hypertension of the metabolic syn- drome. Am J Physiol Heart Circ Physiol 2012; 302(6): H1219-30.
13. [13] Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012; 59(5): 1069-78.
14. [14] Barton M, Carmona R, Morawietz H, et al. Obesity is associated with tissue-specific activation of renal angiotensin-converting en- zyme in vivo: evidence for a regulatory role of endothelin. Hyper- tension 2000; 35(1 Pt 2): 329-36.
15. [15] Marcus Y, Shefer G, Stern N. Adipose tissue renin-angiotensin- aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol 2012; 378(1-2): 1-14.
16. [16] Jing F, Mogi M, Horiuchi M. Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction. Mol Cell Endocrinol 2012; 378(1-2): 23-8.
17. [17] Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin sys- tem: a link between obesity, inflammation and insulin resistance. Obes Rev 2012; 13(2): 136-49.
18. [18] Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89(6): 2548-56.
19. [19] Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunc- tion in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29(24): 2959-71.
20. [20] Gu P, Xu A. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. Endocr Metab Disord 2013; 14(1): 49-58.
21. [21] Yudkin JS, Eringa E, Stehouwer CD. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005; 365(9473): 1817-20.
22. [22] Meijer RI, Serne EH, Smulders YM, van Hinsbergh VW, Yudkin JS, Eringa EC. Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease. Curr Diab Rep 2011; 11(3): 211-7.
23. [23] Ouwens DM, Sell H, Greulich S, Eckel J. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardio- vascular disease. J Cell Mol Med 2010; 14(9): 2223-34.
24. [24] Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27 (Suppl 3): S53-5.
25. [25] Coletta DK, Mandarino LJ. Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria. Am J Physiol Endocrinol Metab 2011; 301(5): E749-55.
26. [26] Dorresteijn JAN, Visseren FLJ, Spiering W. Mechanisms linking obesity to hypertension. Obes Rev 2012; 13(1): 17-26.
27. [27] Virmani R, Burke AP, Kolodgie F. Morphological characteristics of coronary atherosclerosis in diabetes mellitus. Can J Cardiol 2006; 22 (Suppl B): 81B-84B.
28. [28] Vela D, Buja LM, Madjid M, et al. The role of periadventitial fat in atherosclerosis. Arch Pathol Lab Med 2007; 131(3): 481-7.
29. [29] Puri R, Kataoka Y, Uno K, Nicholls SJ. The distinctive nature of atherosclerotic vascular disease in diabetes: pathophysiological and morphological insights. Curr Diab Rep 2012; 12(3): 280-5.
30. [30] Blonde L. State of diabetes care in the United States. Am J Manag Care 2007; 13 (Suppl 2): S36-40.
31. [31] Rizzoni D, Porteri E, Boari GE, et al. Prognostic significance of small-artery structure in hypertension. Circulation 2003; 108(18): 2230-5.
32. [32] Mathiassen ON, Buus NH, Sihm I, et al. Small artery structure is an independent predictor of cardiovascular events in essential hy- pertension. J Hypertens 2007; 25(5): 1021-6.
33. [33] Levy BI, Schiffrin EL, Mourad JJ, et al. Impaired tissue perfusion: a pathologycommon to hypertension, obesity, and diabetes melli- tus. Circulation 2008; 118(9): 968-76.
34. [34] Schelbert HR. Coronary circulatory function abnormalities in insu- lin resistance. Insights from positron emission tomography. J Am Coll Cardiol 2009; 53(5 Suppl): S3-8.
35. [35] Wong TY, Duncan BB, Golden SH, et al. Associations between the metabolic syndrome and retinal microvascular signs: the Athero- sclerosis Risk in Communities study. Invest Ophthalmol Vis Sci 2004; 45(9): 2949-54.
36. [36] Muris DM, Houben AJ, Schram MT, Stehouwer CD. Microvascu- lar dysfunction is associated with a higher incidence of type 2 dia- betes mellitus: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2012; 32(12): 3082-94.
37. [37] De Boer MP, Meijer RI, Wijnstok NJ, et al. Microvascular Dys- function: A Potential Mechanism in the Pathogenesis of Obesity- associated Insulin Resistance and Hypertension. Microcirculation 2012; 19(1): 5-18.
38. [38] Scalia R. The microcirculation in adipose tissue inflammation. Rev Endocr Metab Disord 2013; 14(1): 69-76.
39. [39] Mulvany MJ, Baumbach GL, Aalkjaer C, et al. Vascular remodel- ing. Hypertension 1996; 28(3): 505-6.
40. [40] Safar ME, Nilsson PM, Blacher J, Mimran A. Pulse pressure, arte- rial stiffness, and end-organ damage. Curr Hypertens Rep 2012; 14(4): 339-44.
41. [41] Rizzoni D, Porteri E, Guelfi D, et al. Structural alterations in sub- cutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001; 103(9): 1238-44.
42. [42] Schofield I, Malik R, Izzard A, Austin C, Heagerty A. Vascular structural and functional changes in type 2 diabetes mellitus: evi- dence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002; 106(24): 3037-43.
43. [43] Endemann DH, Pu Q, De Ciuceis C, et al. Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment. Hypertension 2004; 43(2): 399-404.
44. [44] Grassi G, Seravalle G, Scopelliti F, et al. Structural and functional alterations of subcutaneous small resistance arteries in severe hu- man obesity. Obesity 2010; 18(1): 92-8.
45. [45] Grassi G, Seravalle G, Brambilla G, et al. Impact of the metabolic syndrome on subcutaneous microcirculation in obese patients. J Hypertens 2010; 28(8): 1708-14.
46. [46] De Ciuceis C, Porteri E, Rizzoni D, et al. Effects of weight loss on structural and functional alterations of subcutaneous small arteries in obese patients. Hypertension 2011; 58(1): 29-36.
47. [47] Mulvany MJ. Small artery remodelling in hypertension. Basic Clin Pharmacol Toxicol 2012; 110(1): 49-55.
48. [48] Greenstein AS, Price A, Sonoyama K, et al. Eutrophic remodeling of small arteries in type 1 diabetes mellitus is enabled by metabolic control: a 10-year follow-up study. Hypertension 2009; 54(1): 134-41.
49. [49] Rosei EA, Rizzoni D. Small artery remodelling in diabetes. J Cell Mol Med 2010; 14(5): 1030-6.
50. [50] Campbell DJ, Somaratne JB, Jenkins AJ, et al. Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc Diabetol 2011; 10: 80.
51. [51] Lynch FM, Izzard AS, Austin C, et al. Effects of diabetes and hypertension on structure and distensibilty of human small coro- nary arteries. J Hypertens 2012; 30(2): 384-9.
52. [52] Ciuceis CD, Rossini C, Porteri E, et al. Circulating endothelial progenitor cells, microvascular density and fibrosis in obesity be- fore and after bariatric surgery. Blood Press 2013; 22(3): 165-72.
53. [53] Savoia C, Touyz RM, Endemann DH, et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 2006; 48(2): 271-7.
54. [54] Mangoni AA, Giannattasio C, Brunani A, et al. Radial artery com- pliance in young, obese, normotensive subjects. Hypertension 1995; 26(6 Pt 1): 984-8.
55. [55] Brillante DG, O'Sullivan AJ, Johnstone MT, Howes LG. Arterial stiffness and haemodynamic response to vasoactive medication in subjects with insulin-resistance syndrome. Clin Sci (Lond) 2008; 114(2): 139-47.
56. [56] Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51(4): 527-39.
57. [57] Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and com- position of human subcutaneous resistance arteries in essential hy- pertension. Hypertension 1999; 33(1 Pt 2): 569-74.
58. [58] Fellmann L, Nascimento AR, Tibiriça E, Bousquet P. Murine mod- els for pharmacological studies of the metabolic syndrome. Phar- macol Ther 2013; 137(3): 331-40.
59. [59] Yamamoto E, Dong YF, Kataoka K, et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 2008; 52(3): 573-80.
60. [60] Toyama K, Nakamura T, Kataoka K, et al. Telmisartan protects against diabetic vascular complications in a mouse model of obe- sity and type 2 diabetes, partially through peroxisome proliferator activated receptor- -dependent activity. Biochem Biophys Res Commun 2011; 410(3): 508-13.
61. [61] Katz PS, Trask AJ, Souza-Smith FM, et al. Coronary arterioles in type 2 diabetic (db/db) mice undergo a distinct pattern of remodel- ing associated with decreased vessel stiffness. Basic Res Cardiol 2011; 106(6): 1123-34.
62. [62] Trask AJ, Delbin MA, Katz PS, Zanesco A, Lucchesi PA. Differen- tial coronary resistance microvessel remodeling between type 1 and type 2 diabetic mice: impact of exercise training. Vasc Pharmacol 2012; 57(5-6): 187-93.
63. [63] Burlá AK, Lobato NS, Fortes ZB, Oigman W, Neves MF. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int J Cardiol 2013; 165(3): 483-7.
64. [64] Trask AJ, Katz PS, Kelly AP, et al. Dynamic micro- and mac- rovascular remodeling in coronary circulation of obese Ossabaw pigs with metabolic syndrome. J Appl Physiol 2012; 113(7): 1128-40.
65. [65] Villalba N, Martínez P, Briones AM, et al. Differential structural and functional changes in penile and coronary arteries from obese Zucker rats. Am J Physiol Heart Circ Physiol 2009; 297(2): H696-707.
66. [66] Palen DI, Matrougui K. Role of elevated EGFR phosphorylation in the induction of structural remodelling and altered mechanical properties of resistance artery from type 2 diabetic mice. Diabetes Metab Res Rev 2008; 24(8): 651-6.
67. [67] Souza-Smith FM, Katz PS, Trask AJ, et al. Mesenteric resistance arteries in type 2 diabetic db/db mice undergo outward remodeling. PLoS One 2011; 6(8): e23337.
68. [68] Marchesi C, Ebrahimian T, Angulo O, Paradis P, Schiffrin EL. Endothelial nitric oxide synthase uncoupling and perivascular adi- pose oxidative stress and inflammation contribute to vascular dys- function in a rodent model of metabolic syndrome. Hypertension 2009; 54(6): 1384-92.
69. [69] Bouvet C, Belin de Chantemèle E, Guihot AL, et al. Flow-induced remodeling in resistance arteries from obese Zucker rats is associ- ated with endothelial dysfunction. Hypertension 2007; 50(1): 248-54.
70. [70] Belin de Chantemèle EJ, Vessières E, Guihot AL, et al. Type 2 diabetes severely impairs structural and functional adaptation of rat resistance arteries to chronic changes in blood flow. Cardiovasc Res 2009; 81(4): 788-96.
71. [71] Resch M, Schmid P, Amann K, et al. Eplerenone prevents salt- induced vascular stiffness in Zucker diabetic fatty rats: a prelimi- nary report. Cardiovasc Diabetol 2011; 10: 94.
72. [72] Sachidanandam K, Portik-Dobos V, Harris AK, et al. Evidence for vasculoprotective effects of ETB receptors in resistance artery re- modeling in diabetes. Diabetes 2007; 56(11): 2753-8.
73. [73] Sachidanandam K, Hutchinson JR, Elgebaly MM, et al. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr Comp Physiol 2009; 296(4): R952-9.
74. [74] Sachidanandam K, Hutchinson JR, Elgebaly MM, Mezzetti EM, Wang MH, Ergul A. Differential effects of diet-induced dyslipide- mia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes. J Pharmacol Exp Ther 2009; 328(1): 123-30.
75. [75] Hewitt J, Castilla Guerra L, Fernández-Moreno Mdel C, Sierra C. Diabetes and stroke prevention: a review. Stroke Res Treat 2012; 2012: 673187.
76. [76] Osmond JM, Mintz JD, Stepp DW. Preventing increased blood pressure in the obese Zucker rat improves severity of stroke. Am J Physiol Heart Circ Physiol 2010; 299(1): H55-61.
77. [77] Jiménez-Altayó F, Martín A, Rojas S, et al. Transient middle cere- bral artery occlusion causes different structural, mechanical, and myogenic alterations in normotensive and hypertensive rats. Am J Physiol Heart Circ Physiol 2007; 293(1): H628-35.
78. [78] Deutsch C, Portik-Dobos V, Smith AD, Ergul A, Dorrance AM. Diet-induced obesity causes cerebral vessel remodeling and in- creases the damage caused by ischemic stroke. Microvasc Res 2009; 78(1): 100-6.
79. [79] Ergul A, Elgebaly MM, Middlemore ML, et al. Increased hemor- rhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol 2007; 7: 33.
80. [80] Harris AK, Hutchinson JR, Sachidanandam K, et al. Type 2 diabe- tes causes remodeling of cerebrovasculature via differential regula- tion of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes 2005; 54(9): 2638-44.
81. [81] Kelly-Cobbs AI, Harris AK, Elgebaly MM, et al. Endothelial endo- thelin B receptor-mediated prevention of cerebrovascular remodel- ing is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors. J Pharmacol Exp Ther 2011; 337(1): 9-15.
82. [82] Osmond JM, Mintz JD, Dalton B, Stepp DW. Obesity increases blood pressure, cerebral vascular remodeling, and severity of stroke in the Zucker rat. Hypertension 2009; 53(2): 381-6.
83. [83] Vessières E, Freidja ML, Loufrani L, Fassot C, Henrion D. Flow (shear stress)-mediated remodeling of resistance arteries in diabe- tes. Vascul Pharmacol 2012; 57(5-6): 173-8.
84. [84] Buschmann I, Heil M, Jost M, Schaper W. Influence of inflamma- tory cytokines on arteriogenesis. Microcirculation 2003; 10(3-4): 371-9.
85. [85] Belin de Chantemèle EJ, Vessières E, Guihot AL, Toutain B, Lou- frani L, Henrion D. Cyclooxygenase-2 preserves flow-mediated remodelling in old obese Zucker rat mesenteric arteries. Cardiovasc Res 2010; 86(3): 516-25.
86. [86] Freidja ML, Tarhouni K, Toutain B, Fassot C, Loufrani L, Henrion D. The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of type 2 diabetes. Diabetes 2012; 61(6): 1562-72.
87. [87] Stepp DW, Belin De Chantemele EJ. Structural remodeling in the limb circulation: impact of obesity and diabetes. Microcirculation 2007; 14(4-5): 311-6.
88. [88] Georgi MK, Vigilance J, Dewar AM, Frame MD. Terminal arterio- lar network structure/function and plasma cytokine levels in db/db and ob/ob mouse skeletal muscle. Microcirculation 2011; 18(3): 238-51.
89. [89] Frisbee JC. Remodeling of the skeletal muscle microcirculation increases resistance to perfusion in obese Zucker rats. Am J Physiol Heart Circ Physiol 2003; 285(1): H104-11.
90. [90] Stepp DW, Pollock DM, Frisbee JC. Low-flow vascular remodel- ing in the metabolic syndrome X. Am J Physiol Heart Circ Physiol 2004; 286(3): H964-70.
91. [91] Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabe- tes: effects on angiogenesis, vascular remodeling, and wound heal- ing. Int J Vasc Med 2012; 2012: 918267.
92. [92] Rizzoni D, Porteri E, Duse S, et al. Relationship between media-to- lumen ratio of subcutaneous small arteries and wall-to-lumen ratio of retinal arterioles evaluated noninvasively by scanning laser Dop- pler flowmetry. J Hypertens 2012; 30(6): 1169-75.
93. [93] Boillot A, Zoungas S, Mitchell P, et al. Obesity and the microvas- culature: a systematic review and meta-analysis. PLoS One 2013; 8(2): e52708.
94. [94] Tahergorabi Z, Khazaei M. Imbalance of angiogenesis in diabetic complications: the mechanisms. Int J Prev Med 2012; 3(12): 827-38.
95. [95] Xu L, Kanasaki K, Kitada M, Koya D. Diabetic angiopathy and angiogenic defects. Fibrogenesis Tissue Repair 2012; 5(1): 13.
96. [96] Miao CY, Li ZY. The role of perivascular adipose tissue in vascu- lar smooth muscle cell growth. Br J Pharmacol 2012; 165(3): 643-58.
97. [97] Lan TH, Huang XQ, Tan HM. Vascular fibrosis in atherosclerosis. Cardiovasc Pathol 2013; 22: 401-7.
98. [98] Isenovi ER, Soski S, Trpkovi A, et al. Insulin, thrombine, ERK1/2 kinase and vascular smooth muscle cells proliferation. Curr Pharm Des 2010; 16(35): 3895-902.
99. [99] Breen DM, Giacca A. Effects of insulin on the vasculature. Curr Vasc Pharmacol 2011; 9(3): 321-32.
100. [100] Leal Vde O, Mafra D. Adipokines in obesity. Clin Chim Acta 2013; 419: 87-94.
101. [101] Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012; 165(3): 622-32.
102. [102] Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflamma- tion and metabolic disease. Nat Rev Immunol 2011; 11(2): 85-97.
103. [103] Adamczak M, Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol 2013; 33(1): 2-13.
104. [104] Grassi G, Quarti-Trevano F, Seravalle G, Dell'Oro R. Cardiovascu- lar risk and adrenergic overdrive in the metabolic syndrome. Nutr Metab Cardiovasc Dis 2007; 17(6): 473-81.
105. [105] Faber JE, Szymeczek CL, Cotecchia S, et al. Alpha1-adrenoceptor- dependent vascular hypertrophy and remodeling in murine hypoxic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2007; 292(5): H2316-23.
106. [106] Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hyper- tens 2006; 24(6): 983-91.
107. [107] Nguyen Dinh Cat A, Touyz RM. A new look at the renin- angiotensin system--focusing on the vascular system. Peptides 2011; 32(10): 2141-50.
108. [108] Briet M, Schiffrin EL. Vascular Actions of Aldosterone. J Vasc Res 2012; 50(2): 89-99.
109. [109] Briones AM, Touyz RM. Oxidative stress and hypertension: cur- rent concepts. Curr Hypertens Rep 2010; 12(2): 135-42.
110. [110] Amanso AM, Griendling KK. Differential roles of NADPH oxi- dases in vascular physiology and pathophysiology. Front Biosci (Schol Ed) 2012; 4: 1044-64.
111. [111] Bondia-Pons I, Ryan L, Martinez JA. Oxidative stress and inflam- mation interactions in human obesity. J Physiol Biochem 2012; 68(4): 701-11.
112. [112] Yoon YW, Kang TS, Lee BK, et al. Pathobiological role of ad- vanced glycation endproducts via mitogen-activated protein kinase dependent pathway in the diabetic vasculopathy. Exp Mol Med 2008; 40(4): 398-406.
113. [113] Wu S, Song T, Zhou S, et al. Involvement of Na+/H+ exchanger 1 in advanced glycation end products-induced proliferation of vascu- lar smooth muscle cell. Biochem Biophys Res Commun 2008; 375(3): 384-9.
114. [114] Li Y, Liu S, Zhang Z, et al. RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation. PLoS One 2012; 7(4): e35016.
115. [115] Ahmadi N, Eshaghian S, Huizenga R, Sosnin K, Ebrahimi R, Siegel R. Effects of intense exercise and moderate caloric restric- tion on cardiovascular risk factors and inflammation. Am J Med 2011; 124(10): 978-82.
116. [116] Blumenthal JA, Sherwood A, Gullette EC, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemody- namic functioning. Arch Intern Med 2000; 160(13): 1947-58.
117. [117] Reisin E, Jack AV. Obesity and hypertension: mechanisms, cardio- renal consequences, and therapeutic approaches. Med Clin North Am 2009; 93(3): 733-51.
118. [118] Hofsø D, Nordstrand N, Johnson LK, et al. Obesity-related cardio- vascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol 2010; 163(5): 735-45.
119. [119] Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized con- trolled trial. JAMA 2008; 299(3): 316-23.
120. [120] Moschen AR, Molnar C, Geiger S, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 2010; 59(9): 1259-64.
121. [121] Jakicic JM, Otto AD. Treatment and prevention of obesity: what is the role of exercise? Nutr Rev 2006; 64(2 Pt 2): S57-61.
122. [122] Okay DM, Jackson PV, Marcinkiewicz M, Papino MN. Exercise and obesity. Prim Care 2009; 36(2): 379-93.
123. [123] Roque FR, Hernanz R, Salaices M, Briones AM. Exercise training and cardiometabolic diseases-focus on the vascular system. Curr Hypertens Rep 2013; 15(3): 204-14.
124. [124] Hanssen H, Nickel T, Drexel V, et al. Exercise-induced alterations of retinal vessel diameters and cardiovascular risk reduction in obe- sity. Atherosclerosis 2011; 216(2): 433-9.
125. [125] Vinet A, Karpoff L, Walther G, et al. Vascular reactivity at rest and during exercise in middle-aged obese men: effects of short-term, low-intensity, exercise training. Int J Obes (Lond) 2011; 35(6): 820-8.
126. [126] Rizzoni D, Porteri E, De Ciuceis C, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with non insulin-dependent diabetes mellitus. Hypertension 2005; 45(4): 659-65.
127. [127] Agabiti-Rosei E, Heagerty AM, Rizzoni D. Effects of antihyperten- sive treatment on small artery remodelling. J Hypertens 2009; 27(6): 1107-14.
128. [128] Susic D, Varagic J, Ahn J, Frohlich ED. Collagen cross-link break- ers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4(1): 97-101.
129. [129] Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial com- pliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104(13): 1464-70.
130. [130] Goodwill AG, Frisbee SJ, Stapleton PA, James ME, Frisbee JC. Impact of chronic anticholesterol therapy on development of mi- crovascular rarefaction in the metabolic syndrome. Microcircula- tion 2009; 16(8): 667-84.
131. [131] Ledingham JM, Laverty R. Fluvastatin remodels resistance arteries in genetically hypertensive rats, even in the absence of any effect on blood pressure. Clin Exp Pharmacol Physiol 2002; 29(10): 931-4.
132. [132] Ledingham JM, Laverty R. Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats. Clin Exp Pharmacol Physiol 2005; 32(11): 919-25.
133. [133] Briones AM, Rodríguez-Criado N, Hernanz R, et al. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 2009; 54(1): 142-9.
134. [134] Marchesi C, Rehman A, Rautureau Y, et al. Protective role of vascular smooth muscle cell PPAR in angiotensin II-induced vas- cular disease. Cardiovasc Res 2013; 97(3): 562-70.
135. [135] Ashoff A, Qadri F, Eggers R, Jöhren O, Raasch W, Dendorfer A. Pioglitazone prevents capillary rarefaction in streptozotocin- diabetic rats independently of glucose control and vascular endo- thelial growth factor expression. J Vasc Res 2012; 49(3): 260-6.
136. [136] Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296(21): 2572-81.
137. [137] Lu X, Guo X, Karathanasis SK, et al. Rosiglitazone reverses endo- thelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats. Cardiovasc Diabetol 2010; 9: 19.
138. [138] Iglarz M, Touyz RM, Amiri F, Lavoie M, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor- and-acti- vators on vascular remodeling in endothelin-dependent hyperten- sion. Arterioscler Thromb Vasc Biol 2003; 23(1): 45-51.
139. [139] Hernanz R, Martín Á, Pérez-Girón JV, et al. Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxi- dative stress in hypertensive rats: role in vascular function. Br J Pharmacol 2012; 166(4): 1303-19.
140. [140] Sedeek M, Montezano AC, Hebert RL, et al. Oxidative stress, Nox isoforms and complications of diabetes--potential targets for novel therapies. J Cardiovasc Transl Res 2012; 5(4): 509-18.
141. [141] Schiffrin EL. Antioxidants in hypertension and cardiovascular disease. Mol Interv 2010; 10(6): 354-62.
142. [142] Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combat- ing oxidative stress in vascular disease: NADPH oxidases as thera- peutic targets. Nat Rev Drug Discov 2011; 10(6): 453-71.
143. [143] Gibbons GH, Dzau VJ. The emerging concept of vascular remodel- ing. N Engl J Med 1994; 330(20): 1431-8.
144. [144] Sweeney G. Cardiovascular effects of leptin. Nat Rev Cardiol 2010; 7(1): 22-9.